Clinton vows price controls, generic biologics in healthcare plan

Share this article:
Clinton vows price controls on Rx drugs
Clinton vows price controls on Rx drugs
Sen. Hillary Clinton unveiled her healthcare plan, promising to cover all Americans if elected president  –  and taking a few swipes at the pharmaceutical and insurance industries.

“The special interests are having a field day,” she said, describing the Medicare prescription drug benefit as a bonanza for Big Pharma.

The front-running candidate for the Democratic presidential nomination would impose price controls on drugs (“to get prices down in accordance with those in Canada”) and speed the introduction of generic biologics as part of her scheme to cover all Americans  –  in addition to mandating health insurance, making plans portable, combating insurer discrimination against high-risk enrollees and offering small businesses tax credits as incentive to cover their employees. Every American, she said, would have access to the same menu of insurance options that Congress does, including a public plan that would compete with private insurers.

“It's a public-private partnership that provides more choices,” she said, speaking at Broadlawns Medical Center in Des Moines, Iowa.

Clinton boasted that she still bore the scars of her failed 1994 effort to pass universal healthcare legislation, and so did her speech today. Her earlier plan was savaged by the healthcare industry in ads and opinion columns warning that consumers would no longer be able to choose their own doctors if she had her way. The new plan is dubbed “American Health Choices Plan,” and the word “Choice” was a mantra in her speech today.

“Today's plan is simpler but still bold,” she said. “This is not government-run healthcare. There will be no new bureaucracies, and you can keep your doctors and your insurance, if you like it.”
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.